Alectinib

Alectinib is a prescription medication that belongs to a class of drugs known as tyrosine kinase inhibitors. It is specifically designed to target a protein called anaplastic lymphoma kinase (ALK), which is found in certain types of cancer cells. Alectinib is primarily used for the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as ALK-positive.
In patients with ALK-positive NSCLC, the ALK protein promotes the growth and spread of cancer cells. Alectinib works by inhibiting the activity of the ALK protein, thereby slowing down the growth and spread of cancer cells. This medication is typically used in cases where other treatments have not been effective or are no longer working.
Alectinib is available in capsule form and is usually taken once daily, with or without food. The recommended dosage is determined by the healthcare provider based on the patient’s condition, response to treatment, and other factors. It is important to follow the prescribed dosage and schedule to ensure the best possible outcome.
As with any medication, there are potential side effects associated with the use of alectinib. Common side effects may include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. Additionally, patients may experience fatigue, dizziness, or changes in liver function. Report any side effects to the healthcare provider, who can then determine if adjustments to the dosage or treatment plan are necessary.